The cholinergic system in Alzheimer's disease

Current Opinion in Psychiatry

Volumn 15, Issue 3, 2002, Pages 279-284

  Jansen Steur, Ernst N H ^a   Wevers, Andrea ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; RIVASTIGMINE; TACRINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL FEATURE; DIARRHEA; DYSPEPSIA; FATIGUE; HUMAN; INCIDENCE; INSOMNIA; MUSCLE CRAMP; NAUSEA; NURSING HOME; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; UNITED STATES;

EID: 0036232311     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200205000-00009     Document Type: Review

References (45)

1. Diagnosis and Management of Alzheimer's disease and other dementias
2. The parahippocampal gyrus in Alzheimer's disease. Clinical and preclinical neuroanatomic correlates
3. Kinesin-mediated transport of a membrane compartment containing beta-secretase and presenelin-l requires APP
4. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases
5. Apolipoprotein E isoform-specific disruption of phophoinositide hydrolysis: Protection by estrogen and glutathione
6. Does apolipoprotein E genotype influence nicotic receptor binding in Alzheimer's disease
7. Positron emission tomography in evaluation of dementia
8. Cellular mechanisms for amyloid betaprotein activation of rat cholinergic basal forebrain neurons
9. Modulation of nicotinic receptor activity in the central nervous system: A novel approach to the treatment of Alzheimer disease
10. Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development
11. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex
12. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
13. Alzheimer's disease and related disorders
14. Galantamine for Alzheimer's disease
15. Maintaining cognitive function in Alzheimer disease: How effective are current treatments
16. Rivastigmine for Atzheimer's disease
17. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's Disease
18. Brain metabolic and clinical features of rivastigmin Alzheimer's disease
19. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders
20. Cholinesterase inhibitors for Alzheimer's disease
21. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease
22. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788
23. Regulation of gene expression by muscarinic acetylcholine receptors
24. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
25. Nicotinic acetylcholine receptors in Alzheimer's disease
26. Mutation screening of the CHRNA4 and CHRNB2 nicotinic receptor genes in Alzheimer's disease
27. Association analysis of the partially duplicated a7 nicotinic acetylcholine receptor genetic variant and Alzheimer's disease
28. Regional distribution of nicotinic receptor subunit mRNAs in human brain: Comparison between Alzheimer and normal brain
29. Expression of alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease
30. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease-histotopographical correlation with amyloid plaques and hyperphosphorylated tau-protein
31. Alpha 4 but not alpha 3 and 7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease
32. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients
33. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal codex of patients with Alzheimer's disease
34. Epibatidine and ABT 418 reveal selective losses of alpha4 beta2 nicotinic receptors in Alzheimer brains
35. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation
36. Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease-a stereological approach
37. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity
38. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: Postmortem investigations and experimental approaches
39. Classical Alzheimer features and cholinergic dysfunction: Towards a unifying hypothesis?
40. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body disease
41. Amyloid peptide Abeta (1-42) binds selectively and with picomolar affinity to alpha 7 nicotinic acetylcholine receptor
42. beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons
43. β-Amyloid (1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice
44. β-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease
45. Nicotinic acetylcholine receptor α7 and α4β2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus